China Biologic Products (CBPO) 97.08 $CBPO China

New Post Public Reply Private Reply Replies (0) Message Board

Aug 26, 2015 at 9:53 PM

China Biologic Products (CBPO) 97.08 $CBPO

China Biologic Products posts 2Q profit
Automated Insights - Wed Aug 05, 6:30PM CDT
BEIJING (AP) _ China Biologic Products Inc. (CBPO) on Wednesday reported second-quarter net income of $26.7 million.
CBPO: 97.08 (+2.52)

China Biologic Reports Financial Results for the Second Quarter of 2015
PR Newswire - Wed Aug 05, 4:00PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"

, a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2015.
CBPO: 97.08 (+2.52)

Baidu Tanks, But Some China Stocks In U.S. Resilient
at Investor's Business Daily - Tue Jul 28, 5:46PM CDT
Baidu's (BIDU) agonizing drop on Tuesday showed how short investors' fuses have grown with regard to China-based companies. Shares of the Internet search engine plunged to a 13-month low after Q2 profit missed views and the company gave soft...
JP: 8.38 (-0.32), CBPO: 97.08 (+2.52), NOAH: 20.15 (+0.14), DL: 9.65 (-0.34), TANH: 26.19 (+4.11), NTES: 111.43 (-1.09), BIDU: 142.40 (+5.41), YY: 53.45 (+0.47), BONA: 11.61 (+0.09), NORD: 21.05 (-0.47), BABA: 68.66 (+0.09)

China Biologic Products to Report Second Quarter 2015 Financial Results
PR Newswire - Fri Jul 24, 3:01PM CDT
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"

, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2015 financial results on Wednesday, August 5, 2015 after the market closes.
CBPO: 97.08 (+2.52)

China Biologic Products (CBPO) in Focus: Stock Up 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 10, 7:51AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as its shares rose almost 6% on the day.
CBPO: 97.08 (+2.52), AMAG: 63.26 (+4.30)

Celsion's Phase II Breast Cancer Study Interim Data Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 1:30PM CDT
Celsion (CLSN) announced positive data from its going phase II DIGNITY study.
CBPO: 97.08 (+2.52), CLSN: 1.90 (+0.02), INSY: 32.84 (+0.39), EBIO: 3.23 (-0.10)

Pfizer's Once-Daily Xeljanz Application under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 06, 11:50AM CDT
Pfizer's (PFE) NDA for new formulation of Xeljanz under review; response by Feb 2016.
CBPO: 97.08 (+2.52), INSY: 32.84 (+0.39), EBIO: 3.23 (-0.10), PFE: 32.43 (+1.09)

The Medicines Company (MDCO) Jumps: Stock Rises 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 06, 8:25AM CDT
The Medicines Company (MDCO) was a big mover last session, with shares rising over 10% on the day.
CBPO: 97.08 (+2.52), MDCO: 30.40 (+1.48)

IRadimed Raised to Strong Buy on Solid Q1, High Demand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 06, 8:10AM CDT
On Jul 4, 2015, Zacks Investment Research raised MRI compatible IV infusion pump systems provider IRadimed Corp. (IRMD) to a Zacks Rank #1 (Strong Buy).
CBPO: 97.08 (+2.52), INSY: 32.84 (+0.39), IRMD: 25.99 (+1.43), MASI: 40.85 (+1.31)

The Ensign Group Buys Facilities in Arizona & Washington - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 3:40PM CDT
The Ensign Group Inc. (ENSG) acquired 10 skilled nursing facilities and assisted living operations in Arizona and bought a nursing facility in Washington.
CBPO: 97.08 (+2.52), ACHC: 70.41 (+0.26), ENSG: 47.28 (+0.90), CBM: 45.47 (+2.39)

Acadia Healthcare Gains on Belmont Behavioral Health Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 3:05PM CDT
Share price of Acadia Healthcare Company Inc. (ACHC) increased 2.11% ($1.65) to close at $79.98 on Jul 1, 2015, following the acquisition of Belmont Behavioral Health
CBPO: 97.08 (+2.52), ACHC: 70.41 (+0.26), ENSG: 47.28 (+0.90), CBM: 45.47 (+2.39)

Integra LifeSciences (IART) Closes SeaSpine Spin-Off - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 1:10PM CDT
Integra LifeSciences Holdings Corporation (IART) has successfully completed the proposed tax-free spin-off of its subsidiary, SeaSpine Holdings Corporation.
CBPO: 97.08 (+2.52), IART: 59.71 (+0.46), CBM: 45.47 (+2.39), ACHN: 7.34 (+0.24)

Clovis Oncology Starts Rolling NDA Submission for Rociletinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 8:50AM CDT
Clovis (CLVS) initiates the rolling NDA submission for rociletinib with the FDA for the treatment EGFR-mutated non-small cell lung cancer.
CBPO: 97.08 (+2.52), INSY: 32.84 (+0.39), CLVS: 71.51 (+2.01), ACHN: 7.34 (+0.24)

Atara Biotherapeutics (ATRA) Crumbles: Stock Plunges 14.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 7:36AM CDT
Atara Biotherapeutics saw a big move last session, as the company's shares fell nearly 15% on the day
CBPO: 97.08 (+2.52), ATRA: 39.45 (-0.57)

The Ensign Group Buys Nursing Facility, Expands in California - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 12:20PM CDT
The Ensign Group Inc. (ENSG) recently announced the acquisition of The Orchard Post-Acute Care Center ??? a 162-bed skilled nursing facility in Whittier, CA.
CBPO: 97.08 (+2.52), ENSG: 47.28 (+0.90), EBS: 34.14 (+0.90), CBM: 45.47 (+2.39)

Affymetrix Upped to Strong Buy on Solid Q1, Strategic Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 30, 11:40AM CDT
On Jun 30, 2015, Zacks Investment Research raised Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
CBPO: 97.08 (+2.52), EBS: 34.14 (+0.90), CBM: 45.47 (+2.39), AFFX: 9.24 (+0.41)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jun 26, 4:37PM CDT

CBPO: 97.08 (+2.52), OCAT: 3.98 (-0.20), MYGN: 34.33 (+1.36), LPNT: 77.99 (+1.35), JBHT: 72.87 (+0.53), TEDU: 7.97 (-0.06), MYRG: 27.49 (+0.65), TRUE: 4.93 (+0.06), MITL: 7.29 (+0.25), NDAQ: 49.69 (+0.85)

Genomic's Oncotype DCIS Score Betters Treatment Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 25, 1:20PM CDT
Genomic's (GHDX) Oncotyope DCIS Score has been considered the most vital factor in treatment planning by physicians who conducted this study.
CBPO: 97.08 (+2.52), CBM: 45.47 (+2.39), GILD: 106.96 (+4.40), GHDX: 25.95 (+1.78)

Myriad Genetics: Portfolio Offers Hope amid Currency Woes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 23, 1:35PM CDT
To match its existing portfolio strength, Myriad (MYGN) is committed to diversifying its revenue stream into new high-growth diagnostic markets
CBPO: 97.08 (+2.52), MYGN: 34.33 (+1.36), EBS: 34.14 (+0.90), CBM: 45.47 (+2.39)

Qiagen, Hitachi High-Technologies Ink Molecular Testing Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 19, 1:10PM CDT
We believe this tie-up will elevate Qiagen's(QGEN) position in the rapidly changing and highly competitive markets of in-vitro diagnostics and life sciences, applying genetic engineering.
CBPO: 97.08 (+2.52), GILD: 106.96 (+4.40), QGEN: 26.44 (+1.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Southern Company Sparks Swift Power Restoration Post-Isaias

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...